If you've just heard the words "You have mantle cell lymphoma," you're probably terrified.

"This is a very exciting, promising time for mantle cell lymphoma, and how the outcomes have dramatically improved. We know that from the patients that we care for now, as well as large data sets that Dr. Habermann was quoting, and it makes for complicated decision making — so important to really have these long conversations with your physician to make sure you're on the right track with so many choices, and really just encourage folks to consider, as appropriate, participating in clinical trials, so we can continue to build on the gains that we've made over the last decade plus."

"If we haven't provided you hope today, I don't know how we could have done differently. When I started, the median survival was three years in this disease — which meant half the patients died of this disease. What's happened over especially the last decade is just phenomenal. So do what you can to figure out where you are in your disease, and be very comfortable with the team treating you and managing you — and if not, reach out to other institutions. Any opportunity to participate in clinical research will not necessarily benefit you, but will benefit everyone over time."